Search Results for "Drug"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Drug. Results 2461 to 2470 of 2581 total matches.

Lowering Plasma Homocysteine

   
The Medical Letter on Drugs and Therapeutics • Oct 27, 2003  (Issue 1168)
of folate (1 mg), vitamin B 6 (10 85 The Medical Letter ® On Drugs and Therapeutics ...
High plasma homocysteine concentrations, like high cholesterol, have been associated with an increased risk of cardiovascular disease and death (O Nygσrd et al, N Engl J Med 1997; 337:230; RS Vasan et al, JAMA 2003; 289:1251). In one meta-analysis, 25% lower plasma homocysteine concentrations were associated with 11% less coronary heart disease and 19% less stroke (Homocysteine Studies Collaboration, JAMA 2002; 288:2015). Should we be trying to lower serum homocysteine concentrations in our patients?
Med Lett Drugs Ther. 2003 Oct 27;45(1168):85-6 |  Show IntroductionHide Introduction

PSA Reconsidered

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 2012  (Issue 1396)
The Medical Letter® On Drugs and Therapeutics Volume 54 (Issue 1396) August 6, 2012 ...
Three recent publications have focused attention once more on the contentious question of whether men should be screened for prostate cancer by measuring serum concentrations of prostate specific antigen (PSA).
Med Lett Drugs Ther. 2012 Aug 6;54(1396):61 |  Show IntroductionHide Introduction

In Brief: Johnson & Johnson COVID-19 Vaccine Suspended (online only)

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
vaccination. N Engl J Med 2021 April 9 (epub). vaccines drug safety COVID-19 ...
On April 13, 2021, the FDA and CDC advised suspending use of the Johnson & Johnson adenovirus-based COVID-19 vaccine while the agencies investigate 6 cases of cerebral venous sinus thrombosis (CVST) and thrombocytopenia that occurred following administration of the vaccine. In an April 14 emergency meeting, the Advisory Committee on Immunization Practices (ACIP) recommended continuing the suspension until more data become available. About 7 million people in the US have received the Johnson & Johnson vaccine.
Med Lett Drugs Ther. 2021 May 3;63(1623):e1 |  Show IntroductionHide Introduction

COVID Update: Bivalent Vaccine Booster Doses Authorized for Children ≥5 Years Old (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
immunization. Med Lett Drugs Ther 2022; 64:159. 3. CDC. Interim clinical considerations for use of COVID-19 ...
The FDA has expanded its Emergency Use Authorizations (EUAs) for the COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) to permit use of the bivalent formulations of these products (containing mRNA from the original and BA.4/5 Omicron strains of SARS-CoV-2) as a booster dose in children as young as 5 years old (Pfizer) or 6 years old (Moderna). The bivalent Pfizer vaccine had previously been authorized for use in persons ≥12 years old and the bivalent Moderna vaccine in persons ≥18 years old. Bivalent vaccines are not authorized for...
Med Lett Drugs Ther. 2022 Oct 17;64(1661):e1 |  Show IntroductionHide Introduction

Cosmetic Surgery with Lasers

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
Lasers have been used in dermatology for many years. Recently, however, improvements in laser technology have led to much wider use of lasers for treatment of cosmetic skin problems. Many different types of lasers are available; the US Food and Drug Administration gives manufacturers permission to market laser systems for specific indications.
Med Lett Drugs Ther. 1997 Jan 31;39(993):10-1 |  Show IntroductionHide Introduction

Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A

   
The Medical Letter on Drugs and Therapeutics • May 20, 2019  (Issue 1572)
to biologic drugs to distinguish reference products from their biosimilars. TREATMENT OF HEMOPHILIA A – An X ...
The FDA has approved emicizumab-kxwh (Hemlibra – Genentech), a subcutaneously injected, factor IXa- and X-directed antibody, for routine prophylaxis to prevent or reduce bleeding episodes in patients with hemophilia A. Emicizumab is not recommended for treatment of bleeding.
Med Lett Drugs Ther. 2019 May 20;61(1572):77-9 |  Show IntroductionHide Introduction

IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
, have occurred with ferric carboxymaltose. After administration of the drug, patients should be monitored ...
Ferric carboxymaltose (Injectafer – American Regent) is now FDA-approved for IV treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure to improve exercise capacity. Iron deficiency is present in approximately 30% of patients with heart failure; it has been associated with reduced quality of life and increased hospitalization and mortality. Injectafer is the first IV iron preparation to be approved for this indication. It was previously approved for treatment of iron deficiency anemia in children and adults.
Med Lett Drugs Ther. 2024 Feb 5;66(1695):22-4   doi:10.58347/tml.2024.1695d |  Show IntroductionHide Introduction

Cancer Screening

   
Treatment Guidelines from The Medical Letter • Dec 01, 2012  (Issue 124)
for women 40-49 years old. Med Lett Drugs Ther 2009; 51:97. 3. N Shen et al. Mammography in 40-year-old ...
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec;10(124):87-94 |  Show IntroductionHide Introduction

Prevention and Treatment of Injury from Chemical Warfare Agents

   
The Medical Letter on Drugs and Therapeutics • Jan 07, 2002  (Issue 1121)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.
Med Lett Drugs Ther. 2002 Jan 7;44(1121):1-4 |  Show IntroductionHide Introduction

A Vaccine for Rotavirus

   
The Medical Letter on Drugs and Therapeutics • May 21, 1999  (Issue 1053)
The Medical Letter  On Drugs and Therapeutics www.medletter.com Published by The Medical ...
The FDA has approved the marketing of RotaShield, a live oral vaccine for prevention of infantile rotavirus infection. Rotaviruses are segmented double-stranded RNA viruses that are the most common cause of severe diarrhea and dehydration in infants and young children.
Med Lett Drugs Ther. 1999 May 21;41(1053):50 |  Show IntroductionHide Introduction